Bristol-Myers Squibb Company reported its third quarter 2026 financial results, with total revenues increasing 7% to $13.1 billion compared to the same period in 2025. Growth Portfolio revenues increased 12% to $7.7 billion, primarily driven by Opdivo Qvantig, Breyanzi, Reblozyl,
Bristol-Myers Squibb Company Reports Third Quarter Financial Results for 2026
Bristol-Myers Squibb Company reported its third quarter 2026 financial results, with total revenues increasing 7% to $13...
By Dhallo News · October 29, 2026 at 10:12 PM IST
Have feedback on this article?Report error or suggestion
